Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.45 |
| ▸ | RXRA | P19793 | 11/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 2/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131213 | 0.95 | RXRA (0.50) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL3133721 | 0.94 | RXRA (0.41) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL3123416 | 0.92 | RXRA (0.44) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL3130976 | 0.91 | PDE4D (0.44) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL3129460 | 0.90 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL3133720 | 0.90 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL3132303 | 0.90 | RXRA (0.47) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL3126695 | 0.89 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3121025 | 0.88 | PDE4B (0.50) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL3131461 | 0.88 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | claimed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | claimed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.